Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma

被引:2
|
作者
Gao, Min [1 ]
Yuan, Tiejun [1 ]
Zhang, Fangxiang [1 ]
机构
[1] Weifang Peoples Hosp, Dept Otorhinolaryngol, 151 Guangwen St, Weifang 261041, Shandong, Peoples R China
来源
JOURNAL OF BUON | 2021年 / 26卷 / 01期
关键词
nasopharyngeal carcinoma; nimotuzumab; induction chemotherapy; concurrent chemoradiotherapy; efficacy; PHASE-III; FLUOROURACIL; CISPLATIN; GROWTH; DOCETAXEL; HEAD;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the efficacy and safety of nimotuzumab + cisplatin and 5-fluorouracil (PF) induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma. Methods: The clinical data of 126 patients with stage III-IVa nasopharyngeal carcinoma who were admitted to and treated in our department from September 2013 to May 2016 were collected, and the patients were randomly divided into two groups and treated with nimotuzumab combined with PF induction therapy (NPF group, n=65) and induction therapy of docetaxel, cisplatin and fluorouracil (TPF) regimen (TPF group, n=65). After 2 cycles of induction therapy, all the patients received cisplatin combined with concurrent intensity-modulated radiation therapy (IMRT). Moreover, the clinical efficacy, changes in patients' quality of life and incidence of adverse reactions were observed and compared between the two groups, and the survival of the patients was followed up and recorded. Results: The objective response rate (ORR) and disease control rate (DCR) were remarkably higher in NPF group than those in TPF group [78.5% (51/65) vs. 58.5% (38/65), 93.8% (61/65) vs. 80.0% (52/65)] (p=0.014, p=0.019). During induction therapy, the patients in NPF group had notably ameliorated leukopenia compared with those in TPF group (p=0.018). Only 8 cases of skin rash (grade I) occurred in NPF group (p=0.004), which subsided spontaneously after treatment with nimotuzumab. In the stage of concurrent chemoradiotherapy, NPF group exhibited better tolerance to treatment, but there were no statistically significant differences in adverse reactions between the two groups (p>0.05). Besides, according to the scores of functional assessment of cancer therapy-head and neck (FACT-H&N) scale for measuring the quality of life of patients with head and neck neoplasms in the two groups after treatment, the quality-of-life scores were improved to different extents in both groups. Besides, the functional status score [(19.85 +/- 4.74) points vs. (18.14 +/- 4.49) points, p=0.037], head and neck additional items score [(23.95 +/- 5.20) points vs. (22.21 +/- 4.84) points, p=0.040] and total scale score [(108.55 +/- 14.65) points vs. (104.65 +/- 13.23) points, p=0.023] in NPF group were markedly superior to those in TPF group. It was shown in the results of follow-up that the median overall survival (OS) was (18.9 +/- 3.6) months and (16.3 +/- 3.8) months in NPF group and TPF group, respectively. Through log-rank test, it was found that the OS was distinctly longer in NPF group than that in TPF group (p=0.017). Conclusions: Compared with TPF induction chemotherapy, nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy results in better short-term clinical efficacy in treating locally advanced nasopharyngeal carcinoma, higher quality of life and long-term survival rate as well as tolerable adverse reactions.
引用
收藏
页码:116 / 123
页数:8
相关论文
共 50 条
  • [1] Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
    Liu, Zhi-gang
    Zhao, Yu
    Tang, Jiao
    Zhou, Yu-juan
    Yang, Wen-juan
    Qiu, Yan-fang
    Wang, Hui
    [J]. ONCOTARGET, 2016, 7 (17) : 24429 - 24435
  • [2] Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma
    Wu, Sangang
    Wang, Runjie
    Yu, Yifeng
    Zhou, Ping
    Lian, Chenlu
    Wang, Jun
    Lin, Qin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
    Song, Xinmao
    Wang, Shengzi
    Li, Ji
    Yan, Li
    Chen, Fu
    Wang, Jie
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (05) : 1317 - 1324
  • [4] Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma
    Wang, Run-Jie
    Ke, Rui-Quan
    Yu, Yi-Feng
    Lu, Guan-Zhong
    Wu, San-Gang
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [5] Improvement and prognosis analysis of nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma
    Luan, Weihong
    Yuan, Haozhan
    Hou, Wei
    Li, Jing
    Liu, Liping
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (08): : 5630 - 5640
  • [6] Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
    Wang, Lili
    Zhuang, Hengzhao
    Xu, Xiaoyan
    Zhou, Juying
    Jiao, Yang
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Effect of cetuximab combined with IMRT and concurrent chemotherapy in treating locally advanced nasopharyngeal carcinoma
    Yang, Pei
    Liu, Jing
    Yong, Hui
    Ma, Jianli
    Gao, Xiaoping
    [J]. JOURNAL OF BUON, 2021, 26 (01): : 138 - 144
  • [8] Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma
    Xu, Guoqiang
    Wang, Qiaoli
    Wu, Xingrao
    Lv, Chunyan
    Zeng, Guilin
    Xue, Zhihong
    Cao, Ruixue
    Zhang, Nan
    Xiong, Wei
    Huang, Qin
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [9] Neoadjuvant chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone on locally advanced nasopharyngeal carcinoma
    Liu, H.
    Ding, X. R.
    Song, Y. Q.
    Jiang, C.
    Zhong, X. M.
    Hui, H. X.
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2020, 34 (06): : 2115 - 2119
  • [10] Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
    Li, Zhanzhan
    Li, Yanyan
    Yan, Shipeng
    Fu, Jun
    Zhou, Qin
    Huang, Xinqiong
    Shen, Liangfang
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 5445 - 5458